Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Invivyd Inc (IVVD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.58-7.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IVVD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Total company revenue growth | A primary condition in Invivyd Inc's published investment case. The stated target is >= $17.2 million revenue in FY 2025. | Improving | Total revenue falls below $13 million in FY 2025 | Revenue: $14.285M FY2026-Q2; GAAP. Published target: >= $17.2 million revenue in FY 2025. Target period is not explicitly aligned with this observation. Aug 13, 202614,285,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-development business with one product revenue stream showing growth. Its long-term thesis is in a watch state: recent performance is weak versus its industry cohort, though the evidence does not show a fresh thesis break.
The valuation evidence points to IVVD as cheap versus peers, but model confidence is low and the expectations gap is negative. The priced-in assessment is tagged justified, with no fragility gates fired, so the evidence does not indicate that expectations are unusually fragile.
Near term, PEMGARDA revenue growth supports the business, while pivotal trial spending and declining cash weigh on financial strength. Enrollment in the DECLARATION and LIBERTY trials is complete, but clinical progress remains mixed until the expected data and planned regulatory submission. High risk and a 43% estimated miss probability make the next results a meaningful watch point.
The multi-year thesis hinges on continued PEMGARDA growth and whether VYD2311 trial data support the planned regulatory submission. Near term, a guidance cut would be a negative signal, while continued strength from healthcare peers could support sector momentum. Weakening jobs data is another risk to monitor.
Over the next 1 to 3 years, IVVD’s thesis rests on product growth and clinical execution, against weak recent performance, losses, and cash use. The evidence supports a watch-state view with meaningful execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 and Recent Company Highlights PEMGARDA® Commercial Performance & Regulatory Update • PEMGARDA net product revenue was $14.3 million for the quarter ended June 30, 2026, compared to $11.8 million in for the quarter ended June 30, 2025.” “Growth of 21% was driven by increased patient demand.” Revenue was $14.285 million in 2026-Q2.
PEMGARDA net product revenue growth | A primary condition in Invivyd Inc's published investment case. The stated target is >= $13.7 million revenue in Q1 2026. | Intact | PEMGARDA revenue falls below $11 million next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 and Recent Company Highlights PEMGARDA® Commercial Performance & Regulatory Update • PEMGARDA net product revenue was $14.3 million for the quarter ended June 30, 2026, compared to $11.8 million in for the quarter ended June 30, 2025.” “Growth of 21% was driven by increased patient demand.” Revenue was $14.285 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Improvement in EPS losses | A supporting condition in Invivyd Inc's published investment case. The stated target is EPS loss narrows to <= -$0.13 in Q3 2026. | Broken | EPS loss worsens beyond -$0.53 in FY 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.28 → $-0.33 · observed estimates
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-25 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-26 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-27 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-28 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-29 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-07-30 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-07-31 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-01 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-02 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-03 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-04 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-05 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-06 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-07 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-08 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-09 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-10 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-12 | $-0.58 | $89,583,000 | 1 / 3 |
| 2026-08-13 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-14 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-15 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-16 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-17 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-18 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-19 | $-0.28 | $89,598,533 | 2 / 2 |
| 2026-08-20 | $-0.33 | $87,016,333 | 2 / 2 |
| 2026-08-21 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-22 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-23 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-24 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-25 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-26 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-27 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-28 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-29 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-30 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-08-31 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-01 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-02 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-03 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-04 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-05 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-06 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-07 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-08 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-09 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-10 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-11 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-12 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-13 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-14 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-15 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-16 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-17 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-18 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-19 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-20 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-21 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-22 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-23 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-24 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-25 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-26 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-27 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-28 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-29 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-09-30 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-01 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-02 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-03 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-04 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-05 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-06 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-07 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-08 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-09 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-10 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-11 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-12 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-13 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-14 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-15 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-16 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-17 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-18 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-19 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-20 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-21 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-22 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-23 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-24 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-25 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-26 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-27 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-28 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-29 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-30 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-10-31 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-11-01 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-11-02 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-11-03 | $-0.33 | $86,983,000 | 2 / 2 |
| 2026-11-04 | $-0.33 | $86,983,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.